Eric S. Sandler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Eric S. Sandler has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Lars Martin Wagner
Duke University Medical Center
6 shared publications - Aditi Dhir
Department of Pediatric Hematology‐Oncology University of Miami‐Miller School of Medicine/Jackson Health System‐Holtz Children's Hospital Miami Florida USA
5 shared publications - Avery Bodlak
Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado
5 shared publications - Bhuvana A. Setty
Nationwide Children's Hospital, The Ohio State University, Columbus, OH
5 shared publications - Brooke L. Fridley
Department of Pediatrics, Division of Health Services and Outcomes Research, Children’s Mercy Kansas City , Kansas City, Missouri
5 shared publications - Christine A. Pratilas
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, USA
5 shared publications
Latest Publications
- Open Access
- 6 January 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 192 (1) , 25-33
Endocrine dysfunction in long-term survivors of pediatric head and neck rhabdomyosarcoma
Objective: Survivors of pediatric head and neck rhabdomyosarcoma (HNRMS) are at risk of developing endocrinopathies following local treatment, resulting from radiation damage to the pituitary gland, hypothalamus, or thyroid gland, often at a young age. Our aim was to determine the prevalence of endocrine dysfunction in long-term HNRMS survivors and compare the prevalence of anterior pituitary insufficiency (API) among different local treatment strategies: external beam radiation with photons, external beam radiation with protons, microscopically radical surgery combined with external irradiation, and macroscopic radical surgery combined with brachytherapy. Design and methods: Head and neck rhabdomyosarcoma survivors treated between 1993 and 2017, with ≥2 years of follow-up, without recurrent disease or secondary malignancy were eligible for this study. The presence of any endocrine dysfunction was assessed cross-sectionally using Common Terminology Criteria of Adverse Events grading, anthropometrics, and biochemical testing. Retrospective chart review was added to this clinical assessment. Results: Ninety-six survivors with long follow-up time (median, 9 years) were included. Any endocrinopathy was present in 35% of survivors, with 88% having pituitary, 6% peripheral (thyroid), and 6% combined insufficiencies. None had gonadal insufficiency. Growth hormone deficiency was diagnosed in 31 (32%) survivors, with additional pituitary insufficiencies in 12 (39%). In 8%, central precocious puberty preceded API. None of the survivors given brachytherapy had API. Conclusions: The prevalence of pituitary dysfunction in HNRMS survivors is high, emphasizing the importance of systematic endocrine assessment during follow-up, including pubertal development and growth. Efforts should be made to further reduce extraneous irradiation to endocrine organs to prevent dysfunction later in life.
- 6 January 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 192 (1) , 25-33
Open AccessEndocrine dysfunction in long-term survivors of pediatric head and neck rhabdomyosarcoma
Objective: Survivors of pediatric head and neck rhabdomyosarcoma (HNRMS) are at risk of developing endocrinopathies following local treatment, resulting from radiation damage to the pituitary gland, hypothalamus, or thyroid gland, often at a young age. Our aim was to determine the prevalence of endocrine dysfunction in long-term HNRMS survivors and compare the prevalence of anterior pituitary insufficiency (API) among different local treatment strategies: external beam radiation with photons, external beam radiation with protons, microscopically radical surgery combined with external irradiation, and macroscopic radical surgery combined with brachytherapy. Design and methods: Head and neck rhabdomyosarcoma survivors treated between 1993 and 2017, with ≥2 years of follow-up, without recurrent disease or secondary malignancy were eligible for this study. The presence of any endocrine dysfunction was assessed cross-sectionally using Common Terminology Criteria of Adverse Events grading, anthropometrics, and biochemical testing. Retrospective chart review was added to this clinical assessment. Results: Ninety-six survivors with long follow-up time (median, 9 years) were included. Any endocrinopathy was present in 35% of survivors, with 88% having pituitary, 6% peripheral (thyroid), and 6% combined insufficiencies. None had gonadal insufficiency. Growth hormone deficiency was diagnosed in 31 (32%) survivors, with additional pituitary insufficiencies in 12 (39%). In 8%, central precocious puberty preceded API. None of the survivors given brachytherapy had API. Conclusions: The prevalence of pituitary dysfunction in HNRMS survivors is high, emphasizing the importance of systematic endocrine assessment during follow-up, including pubertal development and growth. Efforts should be made to further reduce extraneous irradiation to endocrine organs to prevent dysfunction later in life.
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Data from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
Purpose:The combination of gemcitabine and docetaxel is often used to treat patients with recurrent osteosarcoma. Nab-paclitaxel has preclinical activity against osteosarcoma and is potentially less myelosuppressive than docetaxel. We conducted a prospective multi-institutional phase II trial combining gemcitabine and nab-paclitaxel for patients aged 12 to 30 years with recurrent osteosarcoma and measurable disease.Patients and Methods:A Simon’s two-stage design was used to test a 4-month progression-free survival (PFS-4) of 10% vs. 35%. Patients received nab-paclitaxel 125 mg/m2 and gemcitabine 1,000 mg/m2 weekly × 3 in 4-week cycles. Immunohistochemical analysis of archival tissue and serial assessment of circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) using ultralow passage whole-genome sequencing were performed to identify potential biomarkers of response.Results:Eighteen patients received 56 total cycles (median 2, range 1–12). Two patients (11%) experienced confirmed partial response and six (33%) received >2 cycles. The PFS-4 was 28% (95% confidence interval, 13%–59%). Six patients required dose reductions and three patients were removed due to toxicities. All 18 patients had detectable CTCs and 10 had ctDNA identified. All eight patients with MYC amplification at study entry experienced disease progression.Conclusions:Gemcitabine and nab-paclitaxel demonstrated similar clinical activity and toxicity compared to previous retrospective reports utilizing gemcitabine and docetaxel in patients with recurrent osteosarcoma. Serial analysis of CTC and ctDNA was feasible in this prospective multi-institution study and provides preliminary data on the use of these assays in patients with relapsed disease.
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
Purpose:The combination of gemcitabine and docetaxel is often used to treat patients with recurrent osteosarcoma. Nab-paclitaxel has preclinical activity against osteosarcoma and is potentially less myelosuppressive than docetaxel. We conducted a prospective multi-institutional phase II trial combining gemcitabine and nab-paclitaxel for patients aged 12 to 30 years with recurrent osteosarcoma and measurable disease.Patients and Methods:A Simon’s two-stage design was used to test a 4-month progression-free survival (PFS-4) of 10% vs. 35%. Patients received nab-paclitaxel 125 mg/m2 and gemcitabine 1,000 mg/m2 weekly × 3 in 4-week cycles. Immunohistochemical analysis of archival tissue and serial assessment of circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) using ultralow passage whole-genome sequencing were performed to identify potential biomarkers of response.Results:Eighteen patients received 56 total cycles (median 2, range 1–12). Two patients (11%) experienced confirmed partial response and six (33%) received >2 cycles. The PFS-4 was 28% (95% confidence interval, 13%–59%). Six patients required dose reductions and three patients were removed due to toxicities. All 18 patients had detectable CTCs and 10 had ctDNA identified. All eight patients with MYC amplification at study entry experienced disease progression.Conclusions:Gemcitabine and nab-paclitaxel demonstrated similar clinical activity and toxicity compared to previous retrospective reports utilizing gemcitabine and docetaxel in patients with recurrent osteosarcoma. Serial analysis of CTC and ctDNA was feasible in this prospective multi-institution study and provides preliminary data on the use of these assays in patients with relapsed disease.
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
Supplemental Table S3. Detailed ctDNA results over the course of the study.
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
Supplemental Table S3. Detailed ctDNA results over the course of the study.
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
Supplementary Table S1. Representativeness of Study Participants
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
Supplementary Table S1. Representativeness of Study Participants
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
Supplemental Table S2. Immunohistochemistry Results and Clinical Benefit
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
Supplemental Table S2. Immunohistochemistry Results and Clinical Benefit
- 3 October 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (23) , 5314-5322
Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
Purpose: The combination of gemcitabine and docetaxel is often used to treat patients with recurrent osteosarcoma. Nab-paclitaxel has preclinical activity against osteosarcoma and is potentially less myelosuppressive than docetaxel. We conducted a prospective multi-institutional phase II trial combining gemcitabine and nab-paclitaxel for patients aged 12 to 30 years with recurrent osteosarcoma and measurable disease. Patients and Methods: A Simon’s two-stage design was used to test a 4-month progression-free survival (PFS-4) of 10% vs. 35%. Patients received nab-paclitaxel 125 mg/m2 and gemcitabine 1,000 mg/m2 weekly × 3 in 4-week cycles. Immunohistochemical analysis of archival tissue and serial assessment of circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) using ultralow passage whole-genome sequencing were performed to identify potential biomarkers of response. Results: Eighteen patients received 56 total cycles (median 2, range 1–12). Two patients (11%) experienced confirmed partial response and six (33%) received >2 cycles. The PFS-4 was 28% (95% confidence interval, 13%–59%). Six patients required dose reductions and three patients were removed due to toxicities. All 18 patients had detectable CTCs and 10 had ctDNA identified. All eight patients with MYC amplification at study entry experienced disease progression. Conclusions: Gemcitabine and nab-paclitaxel demonstrated similar clinical activity and toxicity compared to previous retrospective reports utilizing gemcitabine and docetaxel in patients with recurrent osteosarcoma. Serial analysis of CTC and ctDNA was feasible in this prospective multi-institution study and provides preliminary data on the use of these assays in patients with relapsed disease.
- 3 October 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (23) , 5314-5322
Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
Purpose: The combination of gemcitabine and docetaxel is often used to treat patients with recurrent osteosarcoma. Nab-paclitaxel has preclinical activity against osteosarcoma and is potentially less myelosuppressive than docetaxel. We conducted a prospective multi-institutional phase II trial combining gemcitabine and nab-paclitaxel for patients aged 12 to 30 years with recurrent osteosarcoma and measurable disease. Patients and Methods: A Simon’s two-stage design was used to test a 4-month progression-free survival (PFS-4) of 10% vs. 35%. Patients received nab-paclitaxel 125 mg/m2 and gemcitabine 1,000 mg/m2 weekly × 3 in 4-week cycles. Immunohistochemical analysis of archival tissue and serial assessment of circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) using ultralow passage whole-genome sequencing were performed to identify potential biomarkers of response. Results: Eighteen patients received 56 total cycles (median 2, range 1–12). Two patients (11%) experienced confirmed partial response and six (33%) received >2 cycles. The PFS-4 was 28% (95% confidence interval, 13%–59%). Six patients required dose reductions and three patients were removed due to toxicities. All 18 patients had detectable CTCs and 10 had ctDNA identified. All eight patients with MYC amplification at study entry experienced disease progression. Conclusions: Gemcitabine and nab-paclitaxel demonstrated similar clinical activity and toxicity compared to previous retrospective reports utilizing gemcitabine and docetaxel in patients with recurrent osteosarcoma. Serial analysis of CTC and ctDNA was feasible in this prospective multi-institution study and provides preliminary data on the use of these assays in patients with relapsed disease.
- 11 June 2021
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 24 (1) , 141-152
Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry
DIPG generally occurs in young school-age children, although can occur in adolescents and young adults. The purpose of this study was to describe clinical, radiological, pathologic, and molecular characteristics in patients ≥10 years of age with DIPG enrolled in the International DIPG Registry (IDIPGR). Patients ≥10 years of age at diagnosis enrolled in the IDIPGR with imaging confirmed DIPG diagnosis were included. The primary outcome was overall survival (OS) categorized as long-term survivors (LTS) (≥24 months) or short-term survivors (STS) (PPH3F3A or HIST1H3B), TP53, ATRX, and ACVR1 mutations/genome alterations, respectively. Two of 18 patients with IDH1 testing were IDH1-mutant and one was a LTS. The presence or absence of H3 alterations did not affect survival. Patients ≥10 years old with DIPG have a median survival of 13 months. LTS present with longer symptom duration and are likely to be older at presentation compared to STS. ATRX mutation rates were higher in this population than the general DIPG population.
- 11 June 2021
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 24 (1) , 141-152
Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry
DIPG generally occurs in young school-age children, although can occur in adolescents and young adults. The purpose of this study was to describe clinical, radiological, pathologic, and molecular characteristics in patients ≥10 years of age with DIPG enrolled in the International DIPG Registry (IDIPGR). Patients ≥10 years of age at diagnosis enrolled in the IDIPGR with imaging confirmed DIPG diagnosis were included. The primary outcome was overall survival (OS) categorized as long-term survivors (LTS) (≥24 months) or short-term survivors (STS) (PPH3F3A or HIST1H3B), TP53, ATRX, and ACVR1 mutations/genome alterations, respectively. Two of 18 patients with IDH1 testing were IDH1-mutant and one was a LTS. The presence or absence of H3 alterations did not affect survival. Patients ≥10 years old with DIPG have a median survival of 13 months. LTS present with longer symptom duration and are likely to be older at presentation compared to STS. ATRX mutation rates were higher in this population than the general DIPG population.
- Open Access
- 29 July 2020
- Published by Springer Nature in Implementation Science
- Vol. 15 (1) , 1-13
Implementation of family psychosocial risk assessment in pediatric cancer with the Psychosocial Assessment Tool (PAT): study protocol for a cluster-randomized comparative effectiveness trial
Background: Childhood cancer affects and is affected by multiple levels of the social ecology, including social and relational determinants of health (e.g., economic stability, housing, childcare, healthcare access, child and family problems). The 2015 Standards of Psychosocial Care in Pediatric Cancer outline optimal psychosocial care sensitive to these ecological factors, starting with assessment of psychosocial healthcare needs to promote medical and psychosocial outcomes across all children with cancer. To address the first standard of family psychosocial assessment, the Psychosocial Assessment Tool (PAT) is a validated screener ready for broad implementation. Method: The PAT will be implemented across a national sample of 18 pediatric cancer programs ranging in size (annual new patients) in a mixed methods, comparative effectiveness study, guided by the Interactive Systems Framework for Dissemination and Implementation, comparing two implementation strategies. It is hypothesized that implementation will be more successful at the patient/family, provider, and institutional level when training (strategy I) is combined with implementation expanded resources (strategy II). There are three aims: (1) Refine the two implementation strategies using semi-structured qualitative interviews with 19 stakeholders including parent advocates, providers, pediatric oncology organization representatives, healthcare industry leaders; (2) Compare the two theoretically based and empirically informed strategies to implement the PAT in English and Spanish using a cluster-randomized controlled trial across 18 sites. Stratified by size, sites will be randomized to cohort (3) and strategy (2). Outcomes include adoption and penetration of screening (patient/family), staff job satisfaction/burnout (provider), and cost-effective use of resources consistent with family risk (institution); (3) Based on the results of the trial and feedback from the first and second aim, we will develop and disseminate a web-based PAT Implementation Toolkit. Discussion: Use of the PAT across children’s cancer programs nationally can achieve the assessment standard and inform equitable delivery of psychosocial care matched to family need for all patients. Trial Registration: ClinicalTrials.gov, NCT04446728, registered 23 June 2020
- 29 July 2020
- Published by Springer Nature in Implementation Science
- Vol. 15 (1) , 1-13
Open AccessImplementation of family psychosocial risk assessment in pediatric cancer with the Psychosocial Assessment Tool (PAT): study protocol for a cluster-randomized comparative effectiveness trial
Background: Childhood cancer affects and is affected by multiple levels of the social ecology, including social and relational determinants of health (e.g., economic stability, housing, childcare, healthcare access, child and family problems). The 2015 Standards of Psychosocial Care in Pediatric Cancer outline optimal psychosocial care sensitive to these ecological factors, starting with assessment of psychosocial healthcare needs to promote medical and psychosocial outcomes across all children with cancer. To address the first standard of family psychosocial assessment, the Psychosocial Assessment Tool (PAT) is a validated screener ready for broad implementation. Method: The PAT will be implemented across a national sample of 18 pediatric cancer programs ranging in size (annual new patients) in a mixed methods, comparative effectiveness study, guided by the Interactive Systems Framework for Dissemination and Implementation, comparing two implementation strategies. It is hypothesized that implementation will be more successful at the patient/family, provider, and institutional level when training (strategy I) is combined with implementation expanded resources (strategy II). There are three aims: (1) Refine the two implementation strategies using semi-structured qualitative interviews with 19 stakeholders including parent advocates, providers, pediatric oncology organization representatives, healthcare industry leaders; (2) Compare the two theoretically based and empirically informed strategies to implement the PAT in English and Spanish using a cluster-randomized controlled trial across 18 sites. Stratified by size, sites will be randomized to cohort (3) and strategy (2). Outcomes include adoption and penetration of screening (patient/family), staff job satisfaction/burnout (provider), and cost-effective use of resources consistent with family risk (institution); (3) Based on the results of the trial and feedback from the first and second aim, we will develop and disseminate a web-based PAT Implementation Toolkit. Discussion: Use of the PAT across children’s cancer programs nationally can achieve the assessment standard and inform equitable delivery of psychosocial care matched to family need for all patients. Trial Registration: ClinicalTrials.gov, NCT04446728, registered 23 June 2020
- 1 June 2019
- Published by SAGE Publications in Clinical Practice in Pediatric Psychology
- Vol. 7 (2) , 140-150
Implementing Screening With the Psychosocial Assessment Tool (PAT) in Clinical Oncology Practice
Implementing evidence-based approaches to assessment and screening in pediatric psychology practice is important to bridge gaps in clinical care. Identifying specific implementation strategies that result in successful uptake of evidence-based approaches, such as the Psychosocial Assessment Tool (PAT), is necessary. Twelve pediatric cancer programs in three states in the Southeastern United States participated in a 1-day implementation workshop and follow-up group implementation consultation calls to implement the Psychosocial Assessment Tool (PAT), in English and Spanish, in their settings. Participants from these programs completed pre and post implementation questionnaires about their use of the PAT and identified benefits (facilitators) and challenges (barriers) of implementation at the family, provider and institutional levels. Nine of 12 programs (75%) successfully implemented the PAT, with half using both English and Spanish versions. The PAT was administered primarily by social workers and psychologists within the first month after diagnosis. The PAT was viewed as helpful to clinical oncology practice. Prior to the workshop, most participants were very positive about implementation and noted few challenges. Although the benefits of screening with the PAT were maintained through the implementation process, challenges related to staffing and integration of the results in the electronic health record were noted. A 1-day workshop with follow-up consultation calls to support implementation of an evidence-based approach in pediatric cancer was found to be feasible and acceptable. All participants rated the workshop very positively and recommended it. Applications of implementation science to pediatric psychology interventions are promising to advance care. Implications for Impact Statement: Testing how evidence-based approaches can be implemented in clinical practice is an important priority for translating research into practice. This paper shows how the Psychosocial Assessment Tool (PAT), a family psychosocial risk screener, can be implemented into practice in pediatric cancer in English and Spanish using a workshop with consultation calls.
- 1 June 2019
- Published by SAGE Publications in Clinical Practice in Pediatric Psychology
- Vol. 7 (2) , 140-150
Implementing Screening With the Psychosocial Assessment Tool (PAT) in Clinical Oncology Practice
Implementing evidence-based approaches to assessment and screening in pediatric psychology practice is important to bridge gaps in clinical care. Identifying specific implementation strategies that result in successful uptake of evidence-based approaches, such as the Psychosocial Assessment Tool (PAT), is necessary. Twelve pediatric cancer programs in three states in the Southeastern United States participated in a 1-day implementation workshop and follow-up group implementation consultation calls to implement the Psychosocial Assessment Tool (PAT), in English and Spanish, in their settings. Participants from these programs completed pre and post implementation questionnaires about their use of the PAT and identified benefits (facilitators) and challenges (barriers) of implementation at the family, provider and institutional levels. Nine of 12 programs (75%) successfully implemented the PAT, with half using both English and Spanish versions. The PAT was administered primarily by social workers and psychologists within the first month after diagnosis. The PAT was viewed as helpful to clinical oncology practice. Prior to the workshop, most participants were very positive about implementation and noted few challenges. Although the benefits of screening with the PAT were maintained through the implementation process, challenges related to staffing and integration of the results in the electronic health record were noted. A 1-day workshop with follow-up consultation calls to support implementation of an evidence-based approach in pediatric cancer was found to be feasible and acceptable. All participants rated the workshop very positively and recommended it. Applications of implementation science to pediatric psychology interventions are promising to advance care. Implications for Impact Statement: Testing how evidence-based approaches can be implemented in clinical practice is an important priority for translating research into practice. This paper shows how the Psychosocial Assessment Tool (PAT), a family psychosocial risk screener, can be implemented into practice in pediatric cancer in English and Spanish using a workshop with consultation calls.